- Conditions
- Healthy
- Interventions
- SPD503, VYVANSE, SPD503 and VYVANSE
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Hackensack, New Jersey
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–12
of 12
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Attention Deficit Disorder With Hyperactivity
- Interventions
- Guanfacine Extended Release, Placebo
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Pervasive Development Disorders
- Interventions
- placebo, extended-release guanfacine
- Other · Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 5 Years to 14 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 5
- States / cities
- Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 2 more
- Conditions
- Attention-Deficit/Hyperactivity Disorder, Attention Deficit Disorder, Insomnia, Sleep Disorders
- Interventions
- Guanfacine extended-release tablets, Placebo comparator
- Drug
- Lead sponsor
- Children's Specialized Hospital
- Other
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 2
- States / cities
- Hamilton, New Jersey • Toms River, New Jersey
- Conditions
- Healthy
- Interventions
- SPD503, Concerta, SPD503 + Concerta
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Hackensack, New Jersey
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Extended-release Guanfacine Hydrochloride, Atomoxetine Hydrochloride, Placebo Comparator
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 338 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 11
- States / cities
- San Diego, California • Maitland, Florida • Atlanta, Georgia + 8 more
- Conditions
- Attention-deficit/Hyperactivity Disorder
- Interventions
- Extended-release Guanfacine Hydrochloride, Placebo
- Drug · Other
- Lead sponsor
- Shire
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 528 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 27
- States / cities
- Dothan, Alabama • Little Rock, Arkansas • San Diego, California + 24 more
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Guanfacine, Lisdexamfetamine
- Drug
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Alcohol Use Disorder
- Interventions
- Guanfacine Extended Release (XR), Placebo
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana • Newark, New Jersey
- Conditions
- Attention-Deficit/Hyperactivity Disorder
- Interventions
- Extended-release Guanfacine Hydrochloride, Placebo
- Drug · Other
- Lead sponsor
- Shire
- Industry
- Eligibility
- 13 Years to 17 Years
- Enrollment
- 314 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 54
- States / cities
- Dothan, Alabama • Little Rock, Arkansas • Rolling Hills Estates, California + 49 more
- Conditions
- Tourette Disorder, Tourette Syndrome
- Interventions
- placebo, extended-release guanfacine (Intuniv)
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 3
- States / cities
- New Haven, Connecticut • Tampa, Florida • New York, New York
- Conditions
- Intermittent Explosive Disorder, Childhood Aggression, Oppositional Defiant Disorder, Attention Deficit Disorder
- Interventions
- Parent Management Training, Placebo, Intuniv
- Behavioral · Other · Drug
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York